NEW YORK — MDxHealth on Wednesday posted a 22 percent year-over-year increase in its first quarter revenues, topping Wall Street's consensus estimate. For the three-month period ended March 31, ...

The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer.

EsoGuard esophageal precancer testing volume rose 25 percent to 3,034 tests in the first quarter compared to 2,420 tests in Q1 2024.